Larry Anderson, M.D., Ph.D.
Associate Professor

Medical School

UT Health Science Center McGovern Medical School (2000)

Internship

Mayo Clinic (2003), Internal Medicine

Fellowship

Fred Hutchinson Cancer Research Center (2006), Medical Oncology

• Cancer immunology
• Immunotherapy
• MAGE-C1 (CT-7)
• Multiple Myeloma
• Stem Cell Transplantation

Featured Publications

Bone marrow transplant conditioning intensified with liposomal clodronate to eliminate residual host antigen presenting cells fails to ameliorate graft-versus-host disease and increases peri-BMT mortality.

Everse LA, Anderson LD Jr, Rooijen N van, and Mullen CA Transplantation March 2001 71 611-618

Pretransplant tumor antigen-specific immunization of allogeneic bone marrow transplant donors enhances graft-versus-tumor activity without exacerbation of graft-versus-host disease.

Anderson LD Jr, Mori S, Mann S, Savary CA, and Mullen CA Cancer Research October 2000 60 5797-5802

Immunization of allogeneic bone marrow transplant recipients with tumor cell vaccines enhances graft-versus-tumor activity without exacerbating graft-versus-host disease

Anderson LD Jr, Savary CA, and CA Mullen Blood April 2000 95 2426-2433

Enhancement of graft-versus-tumor activity and graft-versus-host disease by pretransplant immunization of allogeneic bone marrow donors with a recipient-derived tumor cell vaccine

Anderson LD Jr, Petropoulos D, Everse LA, and Mullen CA Cancer Research October 1999 59 1525-1530

HER-2/neu peptide specificity in the recognition of HLA-A2 by natural killer cells.

Anderson LD Jr, Hudson JM, Savary CA, Fisk B, Gershenson DM, and Ioannides CG Cancer Immunology Immunotherapy October 1999 48 401-410

Ganciclovir chemoablation of herpes simplex thymidine kinase suicide gene-modified tumors produces tumor necroses and induces systemic immune responses.

Mullen CA, Anderson L, Woods K, Nishino M, and Petropoulos D Human Gene Therapy September 1998 1998 2019-2030

DNA Immunization against the cerebral self antigen Amyloid beta 42 has high potential as safe therapy for Alzheimer’s Disease

Lambracht-Washington D, Qu B, Fu M, Anderson LD Jr, Stuve O, Eager TN, and Rosenberg RN Cellular and Molecular Neurobiology 2011 (In Press)

Identification of MAGE-C1 (CT-7) epitopes for T-cell therapy of Multiple Myeloma

Anderson LD Jr, Cook DR, Yamamoto T, Berger C, Maloney DG, and Riddell SR Cancer Immunology Immunotherapy 2011 (In Press)

Adoptive T-cell therapy for B-cell malignancies

Hudecek M, Anderson LD Jr, Nishida T, and Riddell SR Expert Review of Hematology 2009 2 517-532

Use of Gene-Modified T-cells as Antigen Presenting Cells (T-APC) for Vaccination against Myeloma Antigens.

Anderson LD Jr, Cook DR, Berger C, Maloney D, and Riddell SR Blood November 2007 110 Abstract #2758

• ACS Institutional Research Grant
  Research Grant (2010)
• ASCO Young Investigator Award
  Research Grant (2006)
• K12 Career Development Award
  Research Grant (2006)
• Multiple Myeloma Research Foundation Fellow Award
  Research Grant (2006)

• American Society of Hematology